Competing Against Industry Giants - Zelalem Muluken - S13 Ep160 copertina

Competing Against Industry Giants - Zelalem Muluken - S13 Ep160

Competing Against Industry Giants - Zelalem Muluken - S13 Ep160

Ascolta gratuitamente

Vedi i dettagli del titolo

A proposito di questo titolo

Join us for this episode with Zelalem Muluken, Founder and Chairperson of Zebym Trading, the company behind natural and healthy beverages like Melkam Moringa. For the past eight years, he has been shaping Ethiopia’s beverage industry.In this episode, Zelalem walks us through his story, starting from his early life and career to the moment he decided to invent his own formula and enter a market filled with established giants. He shares the journey of building Zebym, competing for shelf space, navigating operational challenges, and finding a way into the market. Zelalem also talks about leadership, resilience, and the lessons he has learned while growing a company focused on health, quality, and innovation.More from our partners:Dashen BankWebsite: https://dashenbanksc.comTelegram: https://t.me/DashenBankEthiopiaNoah Real EstateWebsite: https://noahrealestateplc.com/BPO Partnership Form:https://forms.gle/PsAVBP1vXCvhKXFP6thereliable.techGIZ:https://www.giz.de/de/downloads/giz2023-en-private-sector-development-in-ethiopia.pdfTo advertise on Meri:https://meri.et/advertiseSocial Linkshttps://t.me/MERI_PODCASThttps://twitter.com/MERI_Podcasthttps://www.instagram.com/meripodcast/https://www.youtube.com/channel/UCzKNuQ80qNSpt2x-7dsazJghttps://youtube.com/@Meriwoch?si=yIpJ3byprnVNwKi1https://youtube.com/@mericlipset?si=wwa0KeQ_Nv2aPy9lhttps://www.tiktok.com/@meripodcasthttps://www.linkedin.com/company/meriethiopian/Copyright Notice for Meri Podcast:All rights reserved.The content featured in this podcast is protected by copyright laws. Unauthorized reproduction, distribution, or modification of any portion of this podcast is strictly prohibited.For permission to use our content, please contact us at info@meri.etThank you for respecting our copyright.

Ancora nessuna recensione